- Home
- RAPT
as 05-20-2024 12:33pm EST
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 151.1M | IPO Year: | 2019 |
| Target Price: | $18.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.98 - $27.35 | Next Earning Date: | 05-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of RAPT Therapeutics Inc. (RAPT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brockstedt Dirk G. | RAPT | CHIEF SCIENTIFIC OFFICER | Jan 5 '24 | Sell | $22.78 | 898 | $20,456.44 | 27,820 | SEC Form 4 |
| HO WILLIAM | RAPT | Chief Medical Officer | Dec 21 '23 | Sell | $21.68 | 2,500 | $54,200.00 | 15,020 | SEC Form 4 |
| HO WILLIAM | RAPT | Chief Medical Officer | Nov 28 '23 | Sell | $13.72 | 1,500 | $20,580.00 | 17,520 | SEC Form 4 |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform
Zacks
7 days ago
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
Simply Wall St.
8 days ago
Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
GuruFocus.com
10 days ago
RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview
MT Newswires
10 days ago
Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy
MT Newswires
10 days ago
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4
Benzinga
11 days ago
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
MT Newswires
11 days ago